The estimated Net Worth of David Roth is at least $1.77 Миллион dollars as of 31 March 2024. David Roth owns over 15,333 units of Syros Pharmaceuticals stock worth over $24,686 and over the last 10 years he sold SYRS stock worth over $136,711. In addition, he makes $1,608,270 as Chief Medical Officer at Syros Pharmaceuticals.
Sign up
David Roth SYRS stock SEC Form 4 insiders trading
David has made over 7 trades of the Syros Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 10,451 units of SYRS stock worth $51,732 on 3 April 2024.
The largest trade he's ever made was exercising 18,875 units of Syros Pharmaceuticals stock on 31 October 2023 worth over $30,389. On average, David trades about 3,917 units every 22 days since 2015. As of 31 March 2024 he still owns at least 15,333 units of Syros Pharmaceuticals stock.
You can see the complete history of David Roth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Roth biography
Dr. David A. Roth M.D. serves as Chief Medical Officer of the Company. Previously, Dr. Roth has been our chief medical officer since December 2015. Previously, Dr. Roth was employed by Infinity Pharmaceuticals, Inc., a pharmaceutical company, from September 2013 until September 2015, serving most recently as its executive vice president and chief medical officer and previously as its senior vice president of clinical development and medical affairs. Prior to joining Infinity, Dr. Roth was the vice president, early development in the oncology business unit of Pfizer Inc., a pharmaceutical company, from 2009 to August 2013. Prior to joining the pharmaceutical industry, Dr. Roth’s experience included over ten years in research and clinical practice as an academic hematologist, and he served on the full-time faculty at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. Dr. Roth received his B.S. from the Massachusetts Institute of Technology and his M.D. from Harvard Medical School in the Harvard MIT Division of Health Sciences and Technology, where he remains on the affiliated faculty.
What is the salary of David Roth?
As the Chief Medical Officer of Syros Pharmaceuticals, the total compensation of David Roth at Syros Pharmaceuticals is $1,608,270. There are 3 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
How old is David Roth?
David Roth is 57, he's been the Chief Medical Officer of Syros Pharmaceuticals since 2015. There are 12 older and 6 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
What's David Roth's mailing address?
David's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Syros Pharmaceuticals
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju и Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
What does Syros Pharmaceuticals do?
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
What does Syros Pharmaceuticals's logo look like?
Complete history of David Roth stock trades at Infinity Pharmaceuticals и Syros Pharmaceuticals
Syros Pharmaceuticals executives and stock owners
Syros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Nancy Simonian,
President, Chief Executive Officer, Director -
Joseph Ferra,
Chief Financial Officer -
Jeremy Springhorn,
Chief Business Officer -
David Roth,
Chief Medical Officer -
Eric Olson,
Chief Scientific Officer -
Gerald Quirk,
Chief Legal & Administrative Officer -
Dr. Nancy A. Simonian M.D.,
Pres, CEO & Director -
Dr. David A. Roth,
Chief Medical Officer -
Dr. Eric R. Olson,
Chief Scientific Officer -
Richard Young,
Director -
Dr. Richard A. Young Ph.D.,
Scientific Founder, Member of Scientific Advisory Board & Director -
Mark Alles,
Independent Director -
Peter Wirth,
Independent Chairman of the Board -
Marsha Fanucci,
Independent Director -
Amir Nashat,
Independent Director -
Phillip Sharp,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
S. Gail Eckhardt,
Director -
Dr. Christian C. Fritz Ph.D.,
Head of Biology -
Naomi Aoki,
VP of Corp. Communications & Investor Relations -
Gerald E. Quirk,
Chief Operations Officer & Sec. -
Jason Haas,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. James E. Bradner M.D.,
Founder -
Alice Tsang Shaw,
Director -
Ventures Fund Iv, L.P.Flags...,
-
Sanj K Patel,
Director -
Vicki L Sato,
Director -
Michael W Bonney,
Director -
Colleen Elizabeth De Simone,
Principal Accounting Officer -
Robert Nelsen,
Director -
Venture Fund Vii, L.P.Arch ...,
-
Kyle D. Kuvalanka,
Chief Operating Officer -
Stephane Bancel,
Director -
Management Co. Vii, L.L.C.P...,
-
Pharm Tech Healthcare Fund ...,
10% owner -
Group, Llc Green Jeremy Red...,
-
Venture Fund Vii Lparch Ven...,
-
Healthcare Ventures Ii, L.P...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Kristin Stephens,
Chief Development Officer -
Deborah Dunsire,
-
Jason Haas,
Chief Financial Officer -
Timothy Tyson,
-
Conley Chee,
President & CEO -
Andrew M. Oh,